How much revenue does InnoPharmax make?

InnoPharmax reported 68.99 million TWD in revenue for fiscal year 2025, up 113.6% from 32.30 million TWD in fiscal year 2024.

What companies are similar to InnoPharmax?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include PharmaEngine, Inc. (4162.TWO), Acepodia, Inc. (6976.TWO), Shine-On BioMedical Co.,Ltd. (6926.TWO).

InnoPharmax Inc. (4172.TWO) Stock

About InnoPharmax Inc.

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and ...

At a glance

InnoPharmax reported revenue of 68.99 million TWD for fiscal year 2025, up 113.6% from fiscal year 2024, and net income of -184.40 million TWD.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.